Riboxin - instructions for use, dose, side effects, contraindications

Active substance:
Inosine (Riboxin)	- 20.0 mg
Excipients:
Methenamine (hexamethylenetetramine)	2.0 mg
Sodium hydroxide solution 1 M	- to pH 7.8-8.6
Water for injections	- up to 1.0 ml

Description: Pcolorless or slightly colored liquid.

Pharmacotherapeutic group:metabolic

ATX: & nbsp

C.01.E.B Other drugs for the treatment of heart disease

Pharmacodynamics:

Inosine is a derivative (nucleoside) of purine, a precursor of adenosine triphosphate (ATP). Refers to a group of drugs that stimulate metabolic processes. Has antihypoxic and antiarrhythmic effect. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism under conditions of hypoxia and in the absence of ATP. Activates the metabolism of pyruvic acid necessary to provide

normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle. Penetrating into cells, it has a positive effect on the metabolic processes in the myocardium - it increases the strength of the heart contractions and promotes more complete relaxation of the myocardium in diastole, as a result of which the stroke volume increases.The mechanism of antiarrhythmic action is not fully understood.

Reduces platelet aggregation, activates the regeneration of tissues (especially the myocardium and mucous membrane of the gastrointestinal tract).

Pharmacokinetics:

Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount, it is excreted by the kidneys.

Indications:

Complex treatment of myocardial infarction, coronary heart disease, cardiac arrhythmias caused by the use of cardiac glycosides, against myocardial dystrophy after infectious diseases. Diseases of the liver (hepatitis, cirrhosis, fatty degeneration).

Operations on an isolated kidney (as a means of pharmacological protection in the short-term shutdown of the circulatory system of the operated organ).

Contraindications:

Hypersensitivity to the drug.

Gout, hyperuricemia.

Pregnancy, breastfeeding, age under 18 years (efficacy and safety not established).

Carefully:

Renal failure.

Pregnancy and lactation:

The use of Riboxin during pregnancy and during breastfeeding is not recommended.

There are no data on the use of the drug in pregnancy.

Dosing and Administration:

The drug is used intravenously slowly, struino or drip (40-60 drops per minute). Treatment is initiated by introducing 200 mg (10 ml of a 20 mg / ml) 1 times a day, then, with good tolerability, the dose was increased to 400 mg (20 ml of a solution of 20 mg / ml) 1-2 times a day. Duration of treatment is 10-15 days.

Bolus of the drug may in acute heart rhythm disturbances in a single dose of 200-400 mg (10-20 ml 20 mg / ml).

For pharmacological protection of kidneys undergoing ischemia Riboxinum administered intravenously in a single dose of 1200 mg (60 ml of a solution of 20 mg / ml) for 5-15 minutes prior to clamping of the renal artery, then another 800 mg (40 ml of a solution of 20 mg / ml ) immediately after the restoration of blood circulation.

For intravenous drip a solution of 20 mg / ml diluted in 5% dextrose (glucose) or 0.9% sodium chloride solution (250 mL).

Side effects:

Allergic reactions: skin itching, skin hyperemia (drug should be discarded).

Rarely: an increase in the concentration of uric acid in the blood, exacerbation of the gout.

Overdose:

At present, no cases of overdose have been reported.

Interaction:

Immunosuppressants reduce the effectiveness of Riboxin.

When used simultaneously with cardiac glycosides, the drug can prevent the occurrence of arrhythmias, enhance the positive inotropic effect.

Special instructions:

Riboxin is not used for emergency correction of cardiac disorders.

In case of renal insufficiency, the use of the drug is possible only if, in the opinion of the doctor, the expected positive effect prevails over the possible risk from use.

During prolonged treatment it is desirable to control the concentration of uric acid in the blood and urine.

Effect on the ability to drive transp. cf. and fur:

There are no data indicating a negative effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Form release / dosage:

Solution for intravenous administration, 20 mg / ml.

Packaging:

5 ml or 10 ml in ampoules of colorless neutral glass type I with a color fracture ring or with a colored dot and notch or without a rift, color point and notch.

Ampoules can additionally be applied with one, two or three colored rings and / or a two-dimensional barcode, and / or alphanumeric-Digital encoding or not additional color rings, a two-dimensional barcode, alphanumeric encoding.

5 ampoules per circuit cell packaging made of polyvinylchloride film and aluminum foil foil or polymer film or without foil and without film. Or 5 ampoules are placed in a prefabricated form (tray) made of cardboard with cells for laying ampoules.

One or two contour cellular packs or cardboard trays, together with the instruction for use and a knife ampoule or scarifier ampoule, or without a knife ampoule and scarifier ampullum placed in a cardboard package (bundle).

Storage conditions:

In the dark place at a temperature of 15 to 25 ° C.

The drug should be stored in places inaccessible to children.

Shelf life:

3 years.

After the expiration date should not be applied.

Terms of leave from pharmacies:On prescription

Registration number:LP-002671

Date of registration:23.10.2014

Date of cancellation:2019-10-23

The owner of the registration certificate:ATOLL, LLC ATOLL, LLC Russia

Manufacturer: & nbsp

OZON PHARM, LLC Russia

Information update date: & nbsp22.10.2015

Illustrated instructions

Instructions

Riboxin (Riboxin)